Triveni Bio

Triveni Bio is a clinical-stage biotechnology company developing first-in-class antibody therapeutics for immunological and inflammatory (I&I) disorders, built on a genetics-informed approach to target discovery combined with advanced antibody engineering. Its lead program TRIV-509 is a dual-specific monoclonal antibody against kallikreins 5 and 7 (KLK5/7) for moderate-to-severe atopic dermatitis, addressing barrier dysfunction, inflammation and itch; TRIV-573 is a half-life-extended, second-generation bispecific that pairs the KLK5/7 mechanism with anti-interleukin-13 (IL-13) and entered Phase 1 in 2026. The pipeline also includes an antibody inhibitor of trypsin 1 and 2 for hereditary pancreatitis driven by PRSS1 mutations. The company launched with a $92M Series A, raised a $115M Series B, and closed a $65M Series C in June 2026, and was named a Fierce 15 biotech of 2025. Triveni Bio is a therapeutics developer, not a software vendor: it publishes no public API, developer portal, SDK or machine-readable specification.

Triveni Bio is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Life Sciences, Pharmaceuticals, and Therapeutics.

Triveni Bio’s developer surface includes engineering blog and 12 more developer resources.

🌐 Visit website 📡 Source on GitHub
11.5/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-17 · rubric v0.11.0
0 APIs
CompanyBiotechnologyLife SciencesPharmaceuticalsTherapeuticsAntibodiesImmunologyDrug DevelopmentClinical TrialsHealthcare

Kin Score

Kin Score Kin Score How this is scored →
scored 2026-08-17 · rubric v0.11.0
Composite quality — 11.5/100 · minimal
Contract Quality 0.0 / 21
Developer Ergonomics 0.4 / 17
Commercial Clarity 3.6 / 17
Operational Transparency 0.0 / 11
Governance 0.0 / 10
Discoverability 4.9 / 9
Regulatory Posture 2.6 / 15
Agent readiness — 0/100 · human only
Machine-Readable Contract 0 / 18
Agentic Access Contract 0 / 10
MCP Server 0 / 12
Machine-Readable Auth 0 / 10
Idempotency 0 / 9
Stable Error Semantics 0 / 8
Request/Response Examples 0 / 7
Rate-Limit Signaling 0 / 7
Typed Event Surface 0 / 6
Agent Skills 0 / 5
Well-Known Catalog 0 / 4
Consent & Bot Identity 0 / 3
A2A Agent Card 0 / 8
Dry-Run / Simulate Mode 0 / 4
Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.
The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/triveni-bio: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Security Posture 1

Authentication, domain security, vulnerability disclosure, and trust-center signals.

Triveni Bio Domain Security

TLSv1.3

SECURITY

Resources

Agent Surfaces 1

MCP servers, agent skills, and machine-readable catalogs

LLMsTxt
LLMsTxt

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity
DomainSecurity

Operate 1

Status, limits, changes, and where to get help

Contact
Contact

Commercial 2

Pricing, plans, and the legal terms of use

PrivacyPolicy
PrivacyPolicy
 TermsOfService
TermsOfService

Company 6

The organization behind the API

Website
Website
 About
About
 Blog
Blog
 BlogRSS
BlogRSS
 Careers
Careers
 LinkedIn
LinkedIn

Other 2

Properties that don't map to a standard resource type

Email
Email
 SecondaryMarket
SecondaryMarket

Source (apis.yml)

apis.yml Raw ↑ 
aid: triveni-bio
name: Triveni Bio
description: 'Triveni Bio is a clinical-stage biotechnology company developing first-in-class antibody therapeutics for immunological
  and inflammatory (I&I) disorders, built on a genetics-informed approach to target discovery combined with advanced antibody
  engineering. Its lead program TRIV-509 is a dual-specific monoclonal antibody against kallikreins 5 and 7 (KLK5/7) for moderate-to-severe
  atopic dermatitis, addressing barrier dysfunction, inflammation and itch; TRIV-573 is a half-life-extended, second-generation
  bispecific that pairs the KLK5/7 mechanism with anti-interleukin-13 (IL-13) and entered Phase 1 in 2026. The pipeline also
  includes an antibody inhibitor of trypsin 1 and 2 for hereditary pancreatitis driven by PRSS1 mutations. The company launched
  with a $92M Series A, raised a $115M Series B, and closed a $65M Series C in June 2026, and was named a Fierce 15 biotech
  of 2025. Triveni Bio is a therapeutics developer, not a software vendor: it publishes no public API, developer portal, SDK
  or machine-readable specification.'
url: https://raw.githubusercontent.com/api-evangelist/triveni-bio/refs/heads/main/apis.yml
image: https://triveni.bio/wp-content/uploads/2025/09/cropped-triveni-icon-1-192x192.png
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.20'
created: '2026-08-05'
modified: '2026-08-05'
tags:
- Company
- Biotechnology
- Life Sciences
- Pharmaceuticals
- Therapeutics
- Antibodies
- Immunology
- Drug Development
- Clinical Trials
- Healthcare
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/triveni-bio-domain-security.yml
- type: Website
  url: https://triveni.bio/
- type: About
  url: https://triveni.bio/about/
- type: Blog
  url: https://triveni.bio/news/
- type: BlogRSS
  url: https://triveni.bio/feed/
- type: PrivacyPolicy
  url: https://triveni.bio/privacy-policy/
- type: TermsOfService
  url: https://triveni.bio/terms-and-conditions/
- type: Careers
  url: https://triveni.bio/about#careers
- type: LinkedIn
  url: https://www.linkedin.com/company/triveni-bio
- type: Contact
  url: https://triveni.bio/contact/
- type: Email
  url: mailto:info@triveni.bio
- type: SecondaryMarket
  url: https://forgeglobal.com/triveni-bio_stock/
- type: LLMsTxt
  url: llms/triveni-bio-llms.txt
x-enrichment:
  date: '2026-08-05'
  status: minimal
  artifacts_added: 2
  pass: local-v1
x-coverage:
  state: none
  reason: not-a-software-company
  detail: Triveni Bio is a clinical-stage antibody therapeutics developer whose entire public site is seven WordPress pages
    (home, about, science, pipeline, news, contact, legal) with no developer, technology, or partner-integration section at
    all; every API-host, docs-host and /.well-known/ probe 404'd and no api./developer./docs. subdomain resolves.
  evidence:
  - url: https://triveni.bio/page-sitemap.xml
    status: 200
  - url: https://triveni.bio/developers
    status: 404
  - url: https://triveni.bio/openapi.json
    status: 404
  - url: https://triveni.bio/.well-known/agent-card.json
    status: 404
  - url: https://triveni.bio/llms.txt
    status: 404
  checked: '2026-08-05'